EMERSON SOARES BERNARDES

Resumo

Bachelor's at FarmĆ”cia from Universidade Federal de Ouro Preto (1998) and doctorate at Applied Imunology from Universidade de SĆ£o Paulo (2004). Has experience in Medicine, acting on the following subjects: galectina-3, carboidratos, trypanosoma cruzi, carcinogĆŖnesis and macrophage. (Text obtained from the CurrĆ­culo Lattes on October 8th 2021)


Possui graduaĆ§Ć£o em FarmĆ”cia pela Universidade Federal de Ouro Preto (1998), mestrado e doutorado em Imunologia BĆ”sica e Aplicada pela Faculdade de Medicina de RibeirĆ£o Preto, Universidade de SĆ£o Paulo (2004), com perĆ­odo de Doutorado SanduĆ­che pela Universidade da California, Davis, USA. Realizou pĆ³s-doutoramento durante o perĆ­odo de 2004 a 2008 pela Faculdade de Medicina da USP-RibeirĆ£o Preto. Trabalhou como pesquisador contratado pelo Instituto de Patologia e Imunologia Molecular da Universidade do Porto - IPATIMUP em Portugal no perĆ­odo de 2008 a 2011. Retornou ao Brasil como pesquisador visitante na Faculdade de Medicina da USP - SĆ£o Paulo (2011-2012) e foi posteriormente contratado como pesquisador no Instituto do CĆ¢ncer do Estado de SĆ£o Paulo (2012-2013). Coordenou um projeto Jovem Pesquisador financiado pela FAPESP (2012-2016 - Desenvolvimento e ProduĆ§Ć£o de RadiofĆ”rmacos Emissores de PĆ³sitrons com AplicaƧƵes DiagnĆ³sticas em Oncologia) e estĆ” integrado como pesquisador Colaborador no Instituto de Pesquisas EnergĆ©ticas e Nucleares (IPEN). Tem atuado na Ć”rea da Glicobiologia, com ĆŖnfase na participaĆ§Ć£o de proteĆ­nas ligantes de carboidratos em processos inflamatĆ³rios e no CĆ¢ncer. Atualmente Ć© professor do Programa de PĆ³s-GraduaĆ§Ć£o do IPEN-USP Tecnologia Nuclear - AplicaƧƵes, tem experiĆŖncia na Ć”rea de RadiofarmĆ”cia, com ĆŖnfase no desenvolvimento de RadiofĆ”rmacos inĆ©ditos para diagnĆ³stico e terapia em Oncologia. (Texto extraĆ­do do CurrĆ­culo Lattes em 08 out. 2021)

Projetos de Pesquisa
Unidades Organizacionais
Cargo

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • Artigo IPEN-doc 26479
    Octreotide nanoparticles showed affinity for in vivo MIA Paca-2 inducted pancreas ductal adenocarcinoma mimicking pancreatic polypeptide-secreting tumor of the distal pancreas (PPoma)
    2019 - BRAGA, THAIS L.; PINTO, SUYENE R.; REIS, SARA R.R. dos; PORTILHO, FILIPE L.; BARROS, ALINE O. da S. de; BERNARDES, EMERSON S.; SANTOS, SOFIA N. dos; ALENCAR, LUCIANA M.R.; RICCI-JUNIOR, EDUARDO; SANTOS-OLIVEIRA, RALPH
    Purpose Pancreatic Polypeptide-secreting tumor of the distal pancreas (PPoma) is a rare, difficult and indolent type of cancer with a survival rate of 5-year in only 10% of all cases. The PPoma is classified as a neuroendocrine tumor (NET) not functioning that overexpresses SSTR 2 (somatostatin receptor subtype 2). Thus, in order to improve the diagnosis of this type of tumor, we developed nanoparticulate drug carriers based on poly-lactic acid (PLA) polymer loaded with octreotide and radiolabeled with Technetium-99 m (99mTc). Methods PLA/PVA octreotide nanoparticles were developed by double-emulsion technique. These nanoparticles were characterized by Atomic Force Microscopy (AFM) and Dynamic Light Scattering (DLS) and radiolabeled with 99mTc by the direct via forming 99mTc-PLA/PVA octreotide nanoparticles. The safety of these nanosystems was evaluated by the MTT cell toxicity assay and their in vivo biodistribution was evaluated in xenografted inducted animals. Results The results showed that a 189 nm sized nanoparticle were formed with a PDI of 0,097, corroborating the monodispersive behavior. These nanoparticles were successfully radiolabeled with 99mTc showing uptake by the inducted tumor. The MTT assay corroborated the safety of the nanosystem for the cells. Conclusion The results support the use of this nanosystem (99mTc-PLA/PVA octreotide nanoparticles) as imaging agent for PPoma.
  • Artigo IPEN-doc 24373
    Microradiopharmaceutical for metastatic melanoma
    2017 - ROSA, THIAGO G.; SANTOS, SOFIA N. dos; PINTO, TEREZINA de J.A.; GHISLENI, DANIELE D.M.; BARJA-FIDALGO, THEREZA C.; RICCI-JUNIOR, EDUARDO; AL-QAHTANI, MOHAMMED; KOZEMPEL, JAN; BERNARDES, EMERSON S.; SANTOS-OLIVEIRA, RALPH
    The purpose of this article was to develop, characterize and test (in vivo) dacarbazine microparticles that may be labeled with 99mTc and Ra-223 for both use: diagnostic and therapy of metastatic melanoma. We developed by double emulsion solvent evaporation methodology the microparticle. The characterization has been done using, Dynamic Light Scattering (DLS) and Scanning Electron Microscopy (SEM). The labeling with 99mTc and Ra-223 has been done by the direct labeling process. Also the formulation has been tested pre-clinically using Balb/c mice inducted with melanoma, performing the the biodistribution and planar imaging. Cytotoxicity evaluation was also done in M3 V cell line. In order to understand the safety aspects of the microparticles, microbiological study (endotoxin and sterility) has been done. Finally, planar imaging was performed to evaluate the diagnosing aspect. The results showed that a 559 nm microparticles was obtained with a spherical shape. The labeling process with 99mTc reached over 90% of efficacy. On the other hand, the labeling process with Ra-223 showed a 70% efficacy. The results in inducted animals demonstrated that the microparticles were able to reach the tumor with a high rate (20%). Also demonstrated a low recognition by the Mononuclear Phagocytic System. The cytotoxicity and the microbiological control, corroborates the safety aspect of these microparticles. The planar image and the possible labeling with Ra-223, corroborates the use as a theragnostic agent for imaging and therapy of Metastatic Melanoma.